

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hastings et al.

Docket No.: PF185D1C2

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

For: Human CCN-Like Growth Factor

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references A-V listed on the attached Form PTO/SB/08. Copies of references E, F, and G are attached.

Copies of references A-C and P-Q were submitted by Applicants or cited by the Examiner in connection with related U.S. Application No. 09/053,587, filed April 1, 1998; copies of references H-O, and V were submitted by Applicants or cited by the Examiner in related U.S. Application No. 08/468,847, filed June 6, 1995; copies of references D and R-U were submitted by Applicants or cited by the Examiner in related U.S. Application No. 09/853,625, filed May 14, 2001; to each of which the instant application claims priority under 35 U.S.C. § 120. Applicants note that references D and R-T were submitted by Applicants as Exhibits A and C-E in Applicants' Amendment and Reply Under 37 C.F.R. § 1.111, filed February 14, 2003. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the files of the above-referenced applications for copies of references A-D, and H-V.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.106(b) concerning


the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed within three months of (i.e., concurrently herewith) the filing of the instant application, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: July 28, 2003



Mark J. Hyman
Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(240) 314-1224

MMW/JMM/MJH/FR/ba

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Gregg A. Hastings
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PF185D1C2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A	US-5,674,718	10-07-1997	Michel-Briand et al	
	B	US-5,408,040	04-18-1995	Grotendorst et al.	
	C	US-4,833,166	05-23-1989	Grosvenor et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	D	WO-02/08284-A2	01-31-2002	Genentech, Inc.		
	E	WO-97/39122-A2	10-23-1997	Muro Pharmaceutical, Inc.		
	F	WO-00/37630-A1	06-29-2000	Genetics Institute, Inc.		
	G	WO-97/39123-A2	10-23-97	Genetics Institute, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Gregg A. Hastings
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	PF185D1C2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	H	EMBL-Genbank Accession No. T31748, ADAMS et al., "EST38075 Homo sapiens cDNA 5' end similar to none," (Jan. 4, 1995)		
	I	EMBL-Genbank Accession No. T31716, ADAMS et al., "EST37509 Homo sapiens cDNA 5' end similar to none," (Jan. 4, 1995)		
	J	EMBL-Genbank Accession No. HSC29F031, "H. sapiens partial cDNA sequence; clone c-29f03" (Nov. 6, 1994)		
	K	EMBL-Genbank Accession No. HAS06A062, "H. sapiens partial cDNA sequence; clone 06A06; stradt (+), single read" (Jun. 4, 1993)		
	L	BORK, "The Modular Architecture of a New Family of Growth Regulators Related to Connective Tissue Growth Factor," <i>FEBS</i> 327(2):125-130 (1993)		
	M	BRADHAM et al., "Connective Tissue Growth Factor: A Cysteine-rich Mitogen Secreted by Human Vascular Endothelial Cells is Related to the SRC-induced Immediate Early Gene Product CEF-10," <i>J. Cell Biol.</i> 114(6):1285-1294 (1991)		
	N	CHEN et al., "Norrie Disease Gene: Characterization of Deletions and Possible Function," <i>Genomics</i> 16:533-535 (1993)		
	O	SIMMONS et al., "Identification of a Phorbol Ester-Repressible v-src-inducible Gene," <i>PNAS USA</i> 86:1178-1182 (1989)		
	P	Geneseq Accession No. W27654 (May 14, 1998)		
	Q	Geneseq Accession No. W44090 (May 12, 1998)		
	R	Pfam Accession No. PF00007, SONNHAMMER, E., "Cys_knot" (1993)		
	S	CHEN et al., "The Angiogenic Factor Cyr61 Activates a Genetic Program for Wound Healing in Human Skin Fibroblasts" <i>J. Biol. Chem.</i> 276(50):47329-47337 (Dec. 14, 2001)		
	T	LAU et al., "The CCN Family of Angiogenic Regulators: The Integrin Connection" <i>Exper. Cell Res.</i> 248:44-57 (1999)		
	U	SNAITH et al., "Genomic Structure and Chromosomal Mapping of the Mouse nov Gene" <i>Genomics</i> 38:425-428 (1996)		
	V	EMBL-Genbank, Accession No. R52804, HILLIER et al., "yg99g12.r1 Homo sapiens cDNA clone 41757 5'," (May-18-1995)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--